NovoCure Limited (NVCR)

Market Cap	1.31B -45.4%
Revenue (ttm)	642.27M +11.2%
Net Income	-177.65M
EPS	-1.61
Shares Out	111.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,337,440
Open	10.98
Previous Close	10.98
Day's Range	10.93 - 11.87
52-Week Range	9.82 - 22.30
Beta	0.73
Analysts	Buy
Price Target	27.75 (+136.37%)
Earnings Date	Feb 26, 2026

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,488
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $27.75, which is an increase of 136.37% from the latest price.

Price Target

$27.75

(136.37% upside)

Analyst Consensus: Buy